Novartis has again indicated that it may sell off its eye care division to help finance the acquisition of an American drugs company, although there are no immediate plans. Daniel Vasella, chairman of the Swiss-based group, has made it clear in recent statements that it considers its pharmaceutical business as ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.